Jennifer Braimon, MD
Endocrinology, Diabetes & Metabolism · Peabody, MANPI 1649373986
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,390 of the $4,901 with a category attached, or 69.2%. 31 manufacturers reported payments, led by Medtronic at 30.3% of the total. Reporting peaked in 2019 at $1,311 and has fallen 53.7% since, to $607 in 2025.
Across 169 payments — averaging $29.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Amgen$556
- AbbVie$467
- Novo Nordisk$304
- Tandem Diabetes Care, Inc.$246
- Astellas Pharma US Inc$223
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$1,25026%
- Food & beverage$3,39069%
- Education$2615%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 13 | $1,484 |
| Amgen | 26 | $556 |
| AbbVie | 33 | $467 |
| Novo Nordisk | 10 | $304 |
| Tandem Diabetes Care, Inc. | 7 | $246 |
| Astellas Pharma US Inc | 4 | $223 |
| Lilly USA, LLC | 11 | $196 |
| Regeneron Healthcare Solutions, Inc. | 6 | $164 |
| Radius Health, Inc. | 6 | $150 |
| Abbott | 7 | $119 |
| Dexcom, Inc. | 3 | $111 |
| AstraZeneca | 2 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| Johnson & Johnson | 4 | $71 |
| Ascendis Pharma Endocrinology Inc | 3 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Antares Pharma, Inc. | 3 | $53 |
| Madrigal Pharmaceuticals | 2 | $43 |
| Zealand Pharma US, Inc. | 2 | $40 |
| Tolmar, Inc. | 2 | $38 |
| Sanofi | 1 | $38 |
| Lifescan, Inc. | 2 | $38 |
| Insulet Corporation | 2 | $34 |
| Recordati_rare_diseases_inc. | 1 | $34 |
| Acella Pharmaceuticals, LLC | 1 | $24 |
| Sandoz | 1 | $22 |
| BETA Bionics, Inc. | 2 | $21 |
| Boehringer Ingelheim | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,250
- EVENITY$112
- t:slim X2 insulin pump$110
- RYBELSUS$107
How this compares
$4,901 in reported general payments places this provider in the 75th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 194 | $296,885 |
| MounjaroTirzepatide | 188 | $261,286 |
| TrulicityDulaglutide | 133 | $178,136 |
| JardianceEmpagliflozin | 130 | $159,792 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $48,941 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $43,337 |
| FarxigaDapagliflozin Propanediol | 33 | $41,293 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $18,767 |
| JanuviaSitagliptin Phosphate | 11 | $14,777 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $13,117 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $12,344 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $11,695 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $10,122 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 94 | $9,629 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 28 | $9,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $196 | $448,720360 claims |
| Novo NordiskOzempic, Novolog | $304 | $301,262216 claims |
| Boehringer IngelheimJardiance | $16 | $159,792130 claims |
| AstraZenecaFarxiga | $91 | $41,29333 claims |
| AbbVieSynthroid | $467 | $4,99466 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $3,456354 claims |
| Sanofi-aventis U.S. LLCLantus | $56 | $2,42013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Peabody
- Helen KaulbachPeabody$43K
- Jason GagliaBoston$2.4M
- Tamer YacoubFall River$775K
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.